S058 Updates in Cutaneous Oncology
DESCRIPTION
Dermatologists’ knowledge is essential to the improvement of diagnosis and management of pediatric and adult patients with skin cancers. A multi-disciplinary panel with expertise in pediatric and adult oncodermatology, cutaneous lymphomas, Mohs surgery, and surgical oncology will provide a high-yield review of pathophysiology, state-of-the-art diagnostic studies, and discuss therapeutic strategies in cutaneous oncology patients. A patient will participate and present “Living with Gorlin syndrome and the power of advocacy”. This session is targeted to dermatologists, residents, and practitioners involved in the care of cutaneous oncology patients.
LEARNING OBJECTIVES
Outline updates in pathogenesis of non-melanoma skin cancers, Merkel cell carcinoma, melanoma, and cutaneous T-cell lymphomas in adult and pediatric patients
Discuss the latest molecular, histopathological, and imaging studies that aid in the diagnosis of cutaneous oncology patients
Identify novel therapeutic approaches and formulate management strategies for adult and pediatric patients with non-melanoma skin cancers, Merkel cell carcinoma, melanoma and cutaneous T-cell lymphomas
DIRECTORS
Jayne S. Joo, MD, FAAD
Allison Weinkle, MD, FAAD
SPEAKERS
Julie Breneiser, PA-C
Gorlin Syndrome Alliance
Ellen J. Kim, MD, FAAD
Department of Dermatology, Perelman School of Medicine
David Miller, MD, PhD, FAAD
Vernon Sondak, MD
Moffitt Cancer Center
Kenneth Y. Tsai, MD, PhD, FAAD
H. Lee Moffitt Cancer Center & Research Institute
DISCLOSURES
Julie Breneiser, PA-C
No financial relationships exist with ineligible companies.
Jayne S. Joo, MD, FAAD
Regeneron – Advisory Board(Fees);
Ellen J. Kim, MD, FAAD
Innate Pharma S.A. – Investigator(Grants/Research Funding); Solgenix LLC – Investigator(Grants/Research Funding);
David Miller, MD, PhD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Avstera Therapeutics Corp – Advisory Board(Stock Options); Bristol Myers Squibb – Consultant (1099 relationship)(Fees); Castle Biosciences – Advisory Board(Fees); Checkpoint Therapeutics – Advisory Board(Honoraria), Advisory Board(Stock Options); Kartos Therapeutics – Investigator(Grants/Research Funding); Merck – Advisory Board(Honoraria); NeoImmuneTech – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria); Xilio Therapeutics – Investigator(Grants/Research Funding);
Vernon Sondak, MD
Bristol-Myers Squibb – Consultant(Honoraria); Merck – Advisory Board(Honoraria); Moderna, Inc. – Consultant (1099 relationship)(Honoraria); Mural Oncology – Consultant (1099 relationship)(Honoraria); Neogene Therapeutics – Other(Grants/Research Funding); Regeneron – Advisory Board(Honoraria); SkylineDx B.V. – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria);
Kenneth Y. Tsai, MD, PhD, FAAD
3CC - Third Culture Capital – Stockholder(No Compensation Received); Altos Labs – Consultant (1099 relationship)(Fees); Ankyra Therapeutics – Independent Contractor(Grants/Research Funding); APIS Assay Technologies – Independent Contractor(Grants/Research Funding); DX Biosciences, Inc – Consultant(Stock Options); Incyte Corporation – Investigator(Grants/Research Funding); NFlection Therapeutics, Inc – Consultant(Fees); Regeneron Pharmaceuticals Inc – Advisory Board(Fees); UpToDate – Independent Contractor(Fees); Verrica Pharmaceuticals Inc – Independent Contractor(Fees);
Allison Weinkle, MD, FAAD
AbbVie – Investigator(No Compensation Received); TEOXANE Laboratories – Investigator(No Compensation Received);